Test and Treat HIV and Viral Hepatitis for People Who Use Drugs and Their Partners in Thailand

Completed

• Conditions: Hepatitis B; A key focus of the study is Hepatitis C, but HIV and hepatitis B are also included. The target population is people who currently inject or use drugs or previously injected or used drugs, as well as; People Who Inject Drugs; Hepatitis C; HIV,

• Registration Number: TCTR20171115002
• Lead Sponsor: Dreamlopments Foundation

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2017-11-15
• Study Completion: 2024-03-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 3000

Inclusion Criteria

Male, female, or transgender.
18 years of age or older.
Former or active injecting or non-injecting drug user reached by harm reduction services or are referred.,
OR
Sexual or life partner of a current or former drug user reached by HRS or referred.
Consenting to participate in the study.
Willing to undertake HIV Ab testing, HCV Ab testing, and HBs Ag and Ab testing. Candidates with evidence (written medical/laboratory report) of prior testing (including positive testing) for HIV, HCV, or HBV infection can also enroll in the cohort study.

Exclusion Criteria

Inability in the opinion of the study staff to provide an informed consent decision to participate in the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
People Who Inject Drug (PWID) who accept HCV, HBV and HIV testing 49 months Propotion,HIV-infected PWID eligible for ART who have initiated ART, remain in care and have HIV suppression a 49 months Propotion,Patients with active HCV infection initiating therapy who achieve Sustained Virological Response (SV 24 weeks Propotion

Secondary Outcome Measures

Name	Time	Method
Incidence of HCV and HIV over the study period among PWID with previous negative testing. 49 months Incidence per 100 person-years,Safety of a community-based approach to treatment and care of HCV for PWID with an all-oral DAA comb 24 weeks Number and proportion of events,Safety of a community-based approach to treatment and care of HIV for PWID. 49 months Number and proportion of events